Detection of HLA Antibodies in Organ Transplant Recipients – Triumphs and Challenges of the Solid Phase Bead Assay by Brian D. Tait
December 2016 | Volume 7 | Article 5701
Review
published: 09 December 2016
doi: 10.3389/fimmu.2016.00570
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Gilles Blancho, 
University of Nantes, France
Reviewed by: 
Stanislaw Stepkowski, 
University of Toledo, USA  
Anne Cesbron, 
Blood Bank, French Southern 
Territories
*Correspondence:
Brian D. Tait  
bdtait@arcbs.redcross.org.au
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 






Tait BD (2016) Detection of 
HLA Antibodies in Organ 
Transplant Recipients – Triumphs 
and Challenges of the Solid 
Phase Bead Assay. 
Front. Immunol. 7:570. 
doi: 10.3389/fimmu.2016.00570
Detection of HLA Antibodies in Organ
Transplant Recipients – Triumphs 




Clinical Services and Research, Australian Red Cross Blood Service, West Melbourne, VIC, Australia
This review outlines the development of human leukocyte antigen (HLA) antibody 
detection assays and their use in organ transplantation in both antibody screening and 
crossmatching. The development of sensitive solid phase assays such as the enzyme-
linked immunosorbent assay technique, and in particular the bead-based technology 
has revolutionized this field over the last 10–15  years. This revolution however has 
created a new paradigm in clinical decision making with respect to the detection of low 
level pretransplant HLA sensitization and its clinical relevance. The relative sensitivities of 
the assays used are discussed and the relevance of conflicting inter-assay results. Each 
assay has its advantages and disadvantages and these are discussed. Over the last 
decade, the bead-based assay utilizing the Luminex® fluorocytometer instrument has 
become established as the “gold standard” for HLA antibody testing. However, there are 
still unresolved issues surrounding this technique, such as the presence of denatured 
HLA molecules on the beads which reveal cryptic epitopes and the issue of appropri-
ate fluorescence cut off values for positivity. The assay has been modified to detect 
complement binding (CB) in addition to non-complement binding (NCB) HLA antibodies 
although the clinical relevance of the CB and NCB IgG isotypes is not fully resolved. 
The increase sensitivity of the Luminex® bead assay over the complement-dependent 
cytotoxicity crossmatch has permitted the concept of the “virtual crossmatch” whereby 
the crossmatch is predicted to a high degree of accuracy based on the HLA antibody 
specificities detected by the solid phase assay. Dialog between clinicians and laboratory 
staff on an individual patient basis is essential for correct clinical decision making based 
on HLA antibody results obtained by the various techniques.
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iNTRODUCTiON
Rejection of solid organ allotransplants can be cellular or antibody mediated. In the majority of 
cases the rejection reaction is directed at human leukocyte antigens (HLAs) expressed on the 
cells of the transplanted organ. While there is no routine test which can be applied to determine 
the cellular immune status of potential transplant recipients, the detection of HLA antibodies, 
particularly those directed at the HLAs of the donor has been at the forefront of donor–recipient 
histocompatibility testing since transplantation became a clinical reality.
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The determination of antibody status is one of the most 
important investigations that is undertaken in potential organ 
transplant recipients. While levels of HLA incompatibility can be 
tolerated due to the quality of immunosuppressive drugs that are 
now available, the presence of antibodies in the recipient specific 
for HLA incompatibilities present in the donor can be devastating 
to the graft.
The first organ transplanted on a routine clinical basis was 
the kidney and a great deal of lessons we have learned about the 
impact of HLA antibodies on transplanted organs was learnt dur-
ing the formative years of clinical renal transplantation.
The pretransplant crossmatch which involves testing the 
recipient’s serum for cytotoxicity against the donor cells (lym-
phocytes) was introduced into the testing algorithm in the 1960s 
in the early days of renal transplantation (1, 2). The test which 
relies on the detection of complement-dependent cytotoxicity 
(CDC) is performed in small microtiter trays. The patient’s serum 
and donor cells are mixed together, rabbit serum as a source of 
complement is added and lysis due to antibodies in the recipient 
specific for the donor cells is detected. The crossmatch test is still 
an essential component of immediate pretransplant testing for 
all organ transplants and is known as the microlymphocytotox-
icity test. A modified form of this test was also used to screen 
patients’ sera for HLA antibodies and to determine specificity. 
This method with modifications was the basis of HLA antibody 
screening for nearly three decades but has been replaced in recent 
years with more sensitive and reproducible assays of antibody 
activity. The evolution of HLA antibody testing and the associ-
ated laboratory and clinical issues that have arisen with the use 
of this new technology forms the basis of this review. Although 
renal transplantation is the basis for many of the lessons we have 
learned using the new methods of antibody detection, they apply 
equally to other forms of solid organ transplantation.
HLA ANTiBODY DeTeCTiON ASSAYS
Complement-Dependent Cytotoxicity
The clinical importance of the pretransplant crossmatch and the 
technology for performing the test was described by Terasaki 
and colleagues (1, 2) and became known as the microlym-
phocytotoxicity assay or CDC. Essentially, the test consists of 
incubating patient serum with potential donor lymphocytes 
to establish if the recipient has donor-specific HLA antibodies 
(HLA-DSA). Rabbit serum as a source of complement is added 
and if HLA-DSA are present lysis of the cells occurs. This lysis 
can be detected by the original method of dye exclusion or by 
later developments which included fluorescence. It was quickly 
appreciated that renal transplant patients with DSA had early 
hyperacute rejection (3, 4). This test was quickly established as 
an essential and non-negotiable pretransplant test, a negative 
result enabling renal transplantation to proceed.
Modifications to the test were made to make the test more 
sensitive such as prolonged incubation and the use of a second 
antibody such as an anti-IgG reagent (5) but there remain several 
technical problems with the test. The assay relies heavily on the 
viability of the donor cells and in the case of deceased donors 
optimal viability is not always achievable. In addition to IgG 
antibodies, the test detects IgM as well as auto antibodies. The 
latter can be overcome to some extent with the use of 1,4-dithi-
othreitol (DTT) (6, 7), although this can result in the loss of some 
IgG antibody (8).
In its original form, the assay was performed using unsepa-
rated lymphocytes from peripheral blood, lymph node, or spleen 
obtained by a gradient separation technique (9). This resulted in 
the detection of both HLA class I antibodies which react with B 
and T lymphocytes and also with HLA class II antibodies which 
react with the class II expressing B cells.
The introduction of cell separation techniques such as ficoll 
gradient separation (9) with subsequent rosetting T lymphocytes 
with sheep red blood cells (10) and then later the use of magnetic 
beads specific for each cell population (11) enabled the distinc-
tion to be made between HLA class I and class II antibodies. 
Other approaches which had varying success were also used.
The main issue with the CDC assay is its sensitivity. The 
development of more sensitive solid phase assays for antibody 
detection has basically replaced the CDC approach, but because 
it is the only functional assay it is still used in many centers as a 
final test of pretransplant compatibility in the form of the CDC 
crossmatch. However, even this test is slowly being replaced by 
the “virtual” crossmatch (see later section).
The CDC assay was modified as an antibody screening 
technique by using a panel of HLA typed cells and testing each 
patient’s serum against this panel. The technique is essentially 
identical to the crossmatch procedure but by using a panel of 
cells it is possible to determine the HLA specificity of antibodies 
present. By testing against both T (which express HLA class I) and 
B lymphocytes (which express both HLA class I and II) it is pos-
sible to characterize both class I and class II antibodies when they 
occur together. An added step of absorbing sera with platelets, 
which express HLA class I but not class II, prior to testing enables 
the determination of class II antibody specificity without the 
added complicating factor of co-occurring class I antibodies (12).
By using a panel of accurate HLA phenotyped cells, it is 
possible to express the result as a panel reactive antibody (PRA) 
percentage (i.e., the percentage of cells in the panel giving a posi-
tive result) in addition to determining HLA antibody specificities. 
The PRA is a useful indicator of the probability of a patient giving 
a negative crossmatch with an unrelated donor.
Flow Cytometry
The flow cytometry crossmatch (FCXM) was introduced into 
clinical practise by Garavoy et al. (13). The principle of the test 
involves incubating donor cells with recipient serum and then 
adding a fluorescein-labeled second anti-human immunoglobulin 
antibody that binds to patient antibody bound to the donor cells. 
The test is read on a flow cytometer, and the degree of positivity is 
expressed as a channel shift. The main advantage of the FCXM is 
its sensitivity for antibody detection over the conventional CDC 
crossmatch (13, 14). In cases where the second antibody is anti-
human IgG, it is not possible to discriminate between comple-
ment binding (CB) and non-complement binding (NCB) HLA 
antibodies. However, if that additional information is required, it 
is possible to use second antibodies to the IgG isotypes and also 
IgM (15, 16). It is also possible to detect antibodies to both class 
FiGURe 1 | The figure represents the principles underlying the 
Luminex bead assay. Each bead has one or more different types of human 
leukocyte antigen (HLA) molecules attached depending on the level of testing 
being performed. If the test serum contains an HLA antibody it will bind to the 
appropriate HLA molecule. This binding can be detected by the use of a 
second phycoerythrin (PE)-labeled anti-human IgG. Each bead gives a 
specific signal when excited by one of the lasers built into the Luminex 
instrument due to the unique intensity of fluorophore embedded in the bead. 
A second laser detects the fluorescent excitation produced by the PE on the 
second antibody. The combination of the two signals indicates first the 
presence (PE fluorescence) and second the specificity (bead fluorescence) of 
the HLA antibody in the test serum.
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I and class II HLA antibodies by using markers to differentiate T 
and B lymphocytes (17, 18).
With the advent of solid phase and in particular bead technol-
ogy, and the interpretation of weak antibodies detected by those 
methods the flow crossmatch is used in many centers to assist in 
clinical decision making. For example, if the flow crossmatch is 
positive in the case where a weak HLA antibody is detected by 
the bead assay (19), a decision may be made to invoke a desensi-
tization protocol or to not proceed with the proposed transplant 
depending on the patient’s transplant and sensitization history. 
Alternatively, a weak HLA antibody detected by the bead assay 
in the presence of a negative flow crossmatch may result in the 
transplant proceeding, but again the patient’s immunological 
history would be a part of the decision making in such a case.
Solid Phase Antibody Detection Assays
Enzyme-Linked Immunosorbent Assay
The enzyme-linked immunosorbent assay (ELISA) was initially 
used in the HLA field for detecting levels of HLA both cell bound 
and free but was adapted for detection of HLA antibodies in 
serum in 1995 (20).
In the modified assay HLA glycoproteins are immune-precip-
itated usually from EBV transformed cell lines, and immobilized 
in the wells of microtiter trays. Sera to be tested are added to the 
wells and antibodies specific for the HLA molecules bind to the 
relevant epitope. After washing an anti-human IgG labeled with 
a reporter molecule such as alkaline phosphatase is then added 
which binds to the primary anti-HLA antibody molecule. After 
repeated washing to remove any unbound secondary antibody, 
a substrate is added which is dephosphorylated by the alkaline 
phosphatase resulting in a color change.
Two levels of testing are achievable using the ELISA tech-
nique. One involves the use of a pool of different class I and 
class II molecules, which essentially gives a positive or negative 
result, and the second utilizes HLA molecules derived from 
single individuals which can be used to determine antibody 
specificity.
The ELISA technique is more sensitive than CDC in detecting 
HLA antibodies (21, 22) but has the potential drawback of not 
distinguishing between complement-fixing and non-comple-
ment-fixing antibodies. This assay however has been used as a 
very effective method for detecting pre- and postsensitization in 
solid organ transplants (23–25) but has been somewhat super-
seded by the introduction of fluorescently labeled beads to which 
HLA molecules have been attached.
Luminex® Bead Technology
The introduction of fluorescently labeled beads revolution-
ized HLA antibody testing during the 1990s. Commercial kits 
are available (One Lambda, Immucor) which consist of beads 
impregnated with differing ratios of two fluorochromes resulting 
in a unique signal for each bead and which have one or several 
types of HLA molecules attached.
The assay involves first the incubation of a patient’s serum with 
the beads. If the patient has HLA antibodies the serum will react 
with the bead expressing the appropriate HLA molecule. After 
washing, the beads are incubated with a secondary antibody, 
usually with a phycoerythrin (PE)-labeled anti-human IgG 
(Figures 1 and 2).
Three levels of testing are possible depending on require-
ments. The first level provides a positive/negative result with 
respect to a patient’s antibody status. In this instance, the beads 
are bound with a large number of class 1 or class 2 molecules 
derived from lymphoblastoid cell lines. Beads used in second 
level testing are bound with molecules derived from a single 
cell line and hence express two HLA molecules for each of the 
HLA loci (HLA-A, -B, -C for class I and HLA-DR, -DQ and -DP 
for class II). This testing is essentially analogous to testing with a 
panel of cells, and therefore, the result can be expressed as a PRA 
percentage. The third level of testing involves the use of beads 
bound with single HLA molecules produced by recombinant 
technology, so called single antigen beads (SAB). These beads 
provide a real advantage of this technology as complex mixtures 
of antibodies can be characterized and HLA specificities accu-
rately determined. This technology is now considered essential 
for the pretransplant testing of sensitized patients.
There are two common methods for the readout. The first 
method involves conventional flow cytometry and measuring 
the channel shift associated with antibody binding. The second 
which has become the most popular approach is the use of the 
Luminex® fluorocytometer which utilizes two lasers, one of 
which excites the fluorochrome in the bead and the other laser 
excites the PE bound to the detection antibody (Figure 3). The 
first readout therefore identifies the unique signal of the bead 
and hence the specificity of the bound HLA molecule, while the 
second readout indicates whether or not antibody is bound to the 
specific HLA molecule.
The degree of fluorescence is expressed as a mean fluorescence 
intensity (MFI), which is normalized by taking into account the 
degree of fluorescence observed with an antibody negative serum 
and with beads to which no HLA molecule is attached. A positive 
control consists of beads bound with PE-labeled human IgG.
FiGURe 3 | The top panel shows the Luminex instrument. There are 
two lasers in the Luminex instrument (bottom panel). The red laser excites 
the fluorophore in the bead which provides a unique signal thereby identifying 
the HLA molecule attached. The green laser excites the phycoerythrin bound 
to the second anti-human IgG antibody indicating IgG antibody in the test 
serum has bound to the appropriate HLA molecule attached to the bead. 
(Modified from a figure provided by Serologicals Corporation.)
FiGURe 2 | The figure outlines the technical steps involved in the assay. The test serum and beads are incubated together at room temperature for 30 min 
and then washed three times with buffer prior to adding the second antibody. A second incubation period of 30 min at room temperature is followed by two further 
washes with buffer and then the mixture is resuspended in phosphate buffered saline for reading in the Luminex instrument.
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SUMMARY COMPARiSON OF 
TeCHNiQUeS
The advantage of the CDC assay is that it is a functional test 
involving antibody containing serum and cells. As a crossmatch 
test it has proved invaluable over the years as a method of avoid-
ing hyperacute rejection due to the presence of HLA-DSA in 
the recipient (3, 4). As an assay for screening patients for HLA 
antibodies it has drawbacks. First, it lacks the sensitivity of the 
other assays described, and second, the assignment of positive 
and negative reactions can be compromised by viability of the 
cells used. It also detects both IgG and IgM HLA antibodies in 
addition to autoantibodies and non-HLA antibodies against 
other cell surface determinants which have no relevance in organ 
transplantation.
In the context of organ transplantation, however, it does have 
the advantage of only detecting CB antibodies. The rationale 
for replacing this assay with the solid phase assays was driven 
primarily by the sensitivity issue and the realization that HLA 
antibodies positive by the solid phase assays but negative by CDC 
in some cases were clinically relevant (24, 26–29).
Before the introduction of the solid phase assays, the 
cell-based flow cytometry assay was introduced into clinical 
practice as a means of providing a more sensitive assay for 
detection of recipient presensitization to donor-specific HLA. 
The flow crossmatch however was not amenable to rapid 
turnaround times and therefore was used primarily in the 
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living related and living unrelated donor situation rather than 
for cadaveric donors.
The issue of whether the flow assay was as sensitive as the 
solid phase assays was the subject of debate for some time but the 
general consensus is that the bead assays are the most sensitive 
assay for detecting HLA antibodies albeit with their own unique 
problems (30).
With respect to the two main solid phase assays the fluores-
cent bead assay has become the gold standard for HLA antibody 
detection and is now used in most transplant testing laboratories. 
The remainder of the review will concentrate on the advantages of 
this technique, and the challenges facing both laboratory workers 
and transplant clinicians in interpreting the data generated by this 
assay.
ADvANTAGeS OF THe LUMiNeX® 
BeAD ASSAY
The Luminex® bead assay is a sensitive method for detection 
of HLA antibodies and represents the current highpoint in the 
evolution of HLA antibody detection assays. The additional 
sensitivity provided by this method has enabled the detection 
of HLA antibodies in potential transplant patients which are 
not detectable by other means, particularly CDC (24, 26–29). 
This increased sensitivity has enabled improvement in the suc-
cess rate of retransplant patients due to the detection of HLA 
presensitization as a result of previous grafts and the subsequent 
avoidance of the relevant HLA specificities on second grafts 
particularly for DP specificities that are not detected by other 
methods (31).
The development of SAB has enabled the dissection and 
specificity determination of complex mixtures of HLA anti-
bodies which is not possible with other techniques. This fine 
level discrimination coupled with the Matchmaker program 
(32) has enabled the description of epitope sequences to 
which HLA antibodies are directed (33–35). Armed with this 
information consideration of sequences of all alleles regardless 
of whether or not they are represented on the bead panel 
allows the identification of all HLA alleles to which a patient 
is immunized.
Obtaining HLA allele information on potential transplant 
recipients has permitted the identification of antibodies to alleles 
within the same antigen group. For example, an A*0301 antibody 
identified in an A*0302 renal transplant patient (36) and an 
A*2402 antibody in an A*2403 patient (37). The only coding 
sequence differences between A*2402 and A*2403 are located at 
positions 166 and 167 which are the unique substitutions within 
the epitope recognized by the A*2403 patient. Historically, the 
presence of A*2403 in a donor would have been considered an 
antigen match for an A*2402 patient yet it clearly represents a 
potential immunizing situation.
Identification of antibodies to DQA1, DQB1, DRB3, -4, -5, and 
DPB1 which is not possible using other antibody screening assays 
has been enabled by the use of beads containing these molecules. 
As a result it has become evident that antibodies to DQ and DP 
(38–42) in addition to DR coexist in organ transplant recipients 
and have been implicated in negative graft outcomes.
iNTeRPReTive CHALLeNGeS 
ASSOCiATeD wiTH THe LUMiNeX® 
BeAD ASSAY
Many of the challenges in interpretation are described in a 
2013 report of Consensus Guidelines by an expert Committee 
under the guidance of The Transplantation Society (43). In addi-
tion, reviews have appeared subsequently, which have further 
contributed to this topic based on more recent data (44, 45). 
Much of the data had been generated in renal transplantation 
but the technical issues apply equally to other forms of organ 
transplantation. The following outlines some of the major issues 
which require consideration when interpreting bead assay data.
Sensitivity
Although the bead assay represents the most sensitive method 
for HLA antibody detection one of the main challenges facing 
clinicians and laboratory scientists is the interpretation of posi-
tive results in the context of a negative CDC crossmatch and/or 
a negative flow crossmatch, and no indication of presensitization 
by any other screening technique. The question of the clinical 
relevance of these HLA antibodies in rejection has been reported 
in renal, heart, and liver transplantation with mixed results 
(46–52). Many factors impact on the clinical relevance of these 
detectable low-level antibodies, one being the MFI cut off for 
positivity used by the reporting center.
Mean Fluorescence intensity
There is no recommended “cut off ” value for MFI positivity. Most 
laboratories set their “cut off ” level for positivity based on levels 
obtained with relevant controls and also on experience gained 
from clinical results obtained. A useful approach, particularly for 
multiparous females or previously grafted patients, is to consider 
each patient on an individual basis. For example, if a previously 
grafted patient has an MFI level for a particular HLA specificity 
to which they were exposed on the first graft and the MFI is above 
the negative values but below the “cut off ” level established in the 
laboratory, this result should be treated with caution. It may indi-
cate a state of presensitization with very low levels of antibody, 
the production of which can be reactivated on repeat exposure 
with a second graft bearing that antigen. Such a result may be 
interpreted differently in a patient with no history of potential 
HLA preimmunization.
Other factors such as the variable amount of target HLA pre-
sent on the bead which can be locus and allele specific (53, 54) 
can result in variation of the MFI obtained. In the absence of an 
agreed standard for the performance of the Luminex® bead assay, 
it is incumbent on each testing laboratory to establish their own 
MFI “cut off ” levels in consultation with their clinical colleagues.
Antibodies to Denatured HLA
The SAB are coated with HLA molecules produced by recom-
binant technology while the screening beads are coated with 
HLA molecules immune-precipitated from cell lines. As a 
result, the SAB express denatured molecules in combination 
with native molecules. The denatured molecules can express 
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cryptic epitopes not normally accessible by antibody molecules, 
and it is not possible to distinguish between these two types of 
antibodies. It would appear intuitive that since the antibody does 
not have access to the cryptic epitope that these antibodies will 
not be clinically relevant. However, a need existed for a means 
of distinguishing between antibodies to denatured and native 
epitopes. One manufacturer responded by introducing ibeads 
which are SAB expressing largely native HLA molecules. These 
beads however were removed from the market in 2014 and the 
manufacturer recommends as an alternative using an acid wash 
procedure.
Antibodies to these exposed cryptic epitopes on denatured 
molecules have been detected in individuals including non-
transfused males (55, 56). Studies comparing antibodies to 
both denatured and native epitopes have demonstrated that the 
antibodies to denatured epitopes have no clinical impact in renal 
or heart transplantation (57, 58). Why antibodies to denatured 
epitopes are found in individuals, particularly non-transfused 
normal males, is a subject of debate. The concept of cross reactiv-
ity with environmental agents such as pathogens or ingested food 
has been suggested (56).
Complement-Fixing and Non-
Complement-Fixing HLA Antibodies
Unlike the CDC assay which by definition only detects CB 
HLA antibodies, the bead assay is designed to detect both CB 
and NCB antibodies. This created debate concerning the NCB 
antibodies detected by the bead assay, and the concern that many 
patients were being denied a transplant on the basis of donor-
specific NCB antibodies, the clinical significance of which was 
not established.
Several modifications have been made to the assay to distin-
guish between CB and NCB HLA antibodies. Using anti-IgG2 
and anti-IgG 4 antibodies to detect NCB antibodies Arnold et al. 
(59) were able to show that up to 40% of re-transplant patients 
on the waiting list had either HLA class 1 or II NCB antibodies. 
Wahrmann et  al. (60) modified the flow-based bead assay by 
adding normal serum as a source of complement and anti-C4d 
as a second antibody and found similar incidence results to 
Arnold (61).
Modification to the Luminex® method of detection was first 
described by Chin and colleagues (62). Their approach involved 
heating the test serum to denature complement and then to add 
purified human C1q to the serum prior to incubation with the 
beads. CB antibody binds the C1q and then is detected using a 
secondary PE-labeled anti-human C1q antibody. This is now the 
method most commonly used by testing laboratories to distin-
guish between CB and NCB HLA antibodies. A commercial C1q 
kit is now available which can detect CB antibodies using either 
beads in the Luminex system or cells, or for use with cell-based 
flow cytometry.
The historical association of CDC positive crossmatches 
with hyperacute or acute rejection led many to believe that CB 
antibodies detected by the C1q assay would be associated with 
rejection while NCB antibodies would not. The reality however is 
that the associations are not so clear cut. Recent studies examin-
ing the clinical associations of antibody-mediated rejection with 
C1q CB and NCB HLA antibodies have yielded some interesting 
observations.
Calp-Inal et al. (63) showed that the incidence of both acute 
and chronic rejection was increased in those with CB DSA HLA 
antibodies pretransplant compared with patients whose DSA 
were NCB antibodies. Guidicelli et  al. (64) demonstrated that 
while de novo CB HLA antibodies were associated with rejec-
tion shortly after their appearance NCB antibodies were also 
associated with rejection in the long term. Piazza et al. (65) also 
demonstrated a strong association of CB antibodies detected in 
the C1q assay with inferior graft survival and also demonstrated 
that the incidence of CB antibodies was increased among those 
patients with HLA class II antibodies, particularly DQ.
By contrast, Thammanichanond et al. (66) were unable to show 
a significant effect of CB antibodies with rejection, albeit it in a 
relatively small cohort of patients. They did however show that 
the CB antibodies had higher levels of MFI than NCB antibodies.
Likewise, Taylor et  al. (67) claim the interpretation of the 
C1q assay is confounded by the level of antibody, the amount 
of denatured HLA on the beads and the interference of comple-
ment. They further question the justification of its use given the 
uncertainty in interpretation and the additional cost involved.
There are points to be made with respect to these studies. First, 
when pretransplant sensitization is involved, in the overwhelm-
ing majority of cases the CDC donor crossmatch is negative and 
therefore lower strength CB antibodies are being selected, which 
will impact on the overall clinical impact. Second, it is known that 
CB IgM antibodies which are not detected in the conventional 
SAB assay can convert to IgG3 CB antibodies posttransplant and 
are detrimental to the graft (68), which can have a confounding 
effect on the data analysis when pretransplant antibodies are 
analyzed. Finally, it appears that NCB antibodies may impact to a 
degree on graft survival at least in the long term (49, 64).
Recently, a C3d assay has been described (69), similar in 
principle to the C1q assay, which measures C3d deposition by 
the addition of human serum to the single bead antigen/antibody 
complex, followed by the addition of an anti-C3D antibody 
labeled with PE. Sicard et al. (69) were able to demonstrate in a 
group of renal transplant patients tested at the time of diagnosis 
for rejection, patients testing positive for C3d had a higher risk of 
graft failure. Interestingly, the C1q assay failed to reach statistical 
significance as a predictor of graft failure.
Comoli et  al. (70) in a recent paper presented results of 
posttransplant testing monitoring for the appearance of de novo 
donor-specific antibodies. Positivity in the C3d assay did not 
predict graft rejection at the first appearance of de novo DSA 
but at the time of rejection there was a strong correlation. They 
also demonstrated that conversion within a single antibody from 
NCB to CB, as demonstrated by C3d positivity, was associated 
with an increasing MFI. The apparent greater association of 
rejection with C3d than with C1q may be a reflection of the stage 
of the complement cascade at which these assays are focused. 
As indicated by Comoli et al. (70), the presence of C1q does not 
predict whether the complement cascade will proceed, or just 
result in C4 deposition on the cell surface. The downstream 
production of C3d may more accurately predict complete com-
plement activation.
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The Prozone effect
One of the technical challenges of using SAB for HLA antibody 
detection is the prozone effect whereby a diluted serum gives a 
higher MFI than the undiluted serum, suggesting an inhibitory 
effect which can be abrogated by dilution. One explanation for the 
inhibitory effect is the presence of IgM antibody of the same HLA 
specificity blocking the binding of the IgG isotype (71). Since IgM 
antibodies tend to be a lower titer than IgG the dilution effect 
was consistent with this interpretation. However, recent research 
suggests that the effect is due to the inhibitory effect of the C3 
component of complement, which is produced as a breakdown 
product of C1. C3 binds to the beads and inhibits the binding 
of IgG antibody present in the test serum (72). This problem 
can be overcome by pre-heating of the test serum to destroy any 
complement activity or by the addition of ethylenediaminetet-
raacetic acid (EDTA) to the wash buffer (73) or by the use of 
dithiothreitol (71) which is also used to eliminate IgM antibodies 
by disruption of disulfide bonds. The possible confounding effect 
of prozone should be always considered when interpreting results 
obtained from using variations of the SAB assay for detection of 
complement-fixing antibodies.
THe DONOR-SPeCiFiC LUMiNeX 
CROSSMATCH
In 2008, Billen et al. (74) reported on the use of commercially 
available beads for donor-specific crossmatching. The beads are 
coated with one of two mouse antibodies with specificity for a 
non-polymorphic sequence on either the class 1 or class 2 mol-
ecules. Using lysates of donor cells the beads are able to capture 
the class 1 and class 2 molecules of the donor which can then be 
reacted with recipient sera and the bound antibody, if present, 
labeled with a fluorescently labeled second antibody and read 
as per the conventional bead assay. Billen et  al. compared the 
results obtained in a group of renal patients with the cell-based 
FCXM results. They demonstrated a sensitivity using the bead 
crossmatch of 89% for class 1 and 68% for class 2. Interestingly, 
they failed to detect antibodies to HLA-DQ and -DP antigens by 
the bead crossmatch which compromised the value of the LUXM 
as an alternative B cell crossmatch technique.
Billen et  al. (75) further reported on a group of 165 CDC 
crossmatch negative patients, 32 of whom had bead positive 
crossmatches. There was no difference in acute rejection free sur-
vival when the CDC-bead + crossmatch group were compared 
with the CDC-bead − crossmatch group. However, the group of 
patients with bead positive crossmatches due to class 1 antibodies 
had an inferior long-term 5 years survival (41% compared with 
70% for the crossmatch negative group). Positivity for class 2 
antibodies had no effect.
Guillaume et al. (76) demonstrated that the LUXM can detect 
class 1 antibodies with an MFI as low as 2,300 in the SAB tech-
nique and 1,300 for class 2. They confirmed the failure to detect 
HLA-DP antibodies and in addition reported on the failure to 
detect HLA-C.
Recently, Chaidaroglou et al. (77) reported on a comparison 
of SAB, FCXM, and LUXM for detection of DSA in a group 
of heart transplant recipients. They found that there was good 
agreement between SAB and FCXM but not between LUXM and 
the other two techniques. They questioned the value of LUXM as 
a technique for prediction or monitoring.
It would seem based on published data to date that the LUXM 
cannot be recommended as a stand-alone method for organ 
allocation.
THe viRTUAL CROSSMATCH
The introduction of solid phase assays and the realization that 
there were a number of patients whose antibodies were detectable 
by these methods but were negative by the CDC crossmatch cast 
some doubt on the complete reliance on the CDC crossmatch as 
a final test of recipient/donor compatibility. Since antibodies with 
MFI values between 10,000 and 20,000 are required to obtain 
positive T cell CDC crossmatches in approximately 90% of cases 
(78), there are clearly some cases where clinically relevant HLA 
antibodies which are not detected by the conventional cross-
match. The use of specific and sensitive methods for antibody 
detection and in particular the HLA SAB allowed for the first time 
a complete picture of the HLA immunization status of individual 
patients. From this the concept of a “virtual crossmatch” (VXM) 
was established (79). The VXM takes into account the HLA 
antibody profile of a patient and predicts which donors will be 
crossmatch negative. This approach has been used successfully 
in renal transplantation. Johnson et al. (80) have reported on a 
large cohort of patients where the final decision to transplant was 
based on SAB results rather the FCXM result. When analyzed 
for clinical outcome based on whether the FCXM was positive 
or negative, despite the fact the FCXM positive group were more 
“at risk” than the FCXM negative group, the transplant outcomes 
were comparable, justifying the use of the VXM in preference to 
the results obtained by FCXM.
Eby et  al. (81) have demonstrated the value of the VXM in 
pancreas transplants as part of the United Network of Organ 
Sharing in the USA. Pancreata imported from Networks 3 and 
4 and transplanted on the basis of VXM had a cold ischemia 5 h 
shorter than the cases where a FCXM was performed prior to 
transplant without any compromise in rejection or graft survival 
incidences.
More centers are expected to rely on the VXM as a prospective 
guide to the suitability of transplantation as data on the reliability 
of this procedure is accumulated.
USe OF THe ANTiGeN BeAD  
ASSAY – LeSSONS LeARNeD
The introduction of solid phase HLA antibody detection 
methods and in particular the bead assays have revolutionized 
the clinical management of sensitized patients. However, the 
introduction of this new technology has posed questions con-
cerning the interpretation of generated data which still require 
resolution.
The “cut off ” MFI values used for assigning positivity vary 
greatly between laboratories. How much this is due to technical 
variation and how much is based on correlation with clinical 
experiences of the local transplant center is difficult to ascertain. 
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Every testing laboratory must determine based on the local per-
formance of the assay and from clinical experience a “cut off ” that 
reflects the level at which antibodies are deemed to be clinically 
relevant. However in this context, it is imperative to consider the 
immunological history of the patient. Borderline values or values 
obtained with antibodies below the “cut off ” may be reflective of 
an increased risk of rejection in patients who have been previ-
ously exposed to the particular antigen to which the antibody 
is directed either by pregnancy or previous grafts. One group 
of patients of particular interest are those who have undergone 
desensitization protocols. “Cut off ” values therefore should be a 
guide and not rigidly enforced without careful consideration of 
the patients’ histories.
The interpretation of HLA antibody results obtained with 
CB fixing assays requires careful interpretation. The prozone 
effect needs to be considered in patients who are known to be 
sensitized but test negative in the CB antibody assays. These 
patients should in addition be tested at a dilution or treated 
with EDTA or DTT prior to testing. HLA antibodies which test 
negative with the CB binding assays should not automatically 
be dismissed as clinically irrelevant. Although the data suggest 
in renal transplantation that NCB HLA antibodies are not as 
damaging to the graft as CB HLA antibodies, and tend to have 
lower MFI values, there are data which indicate that they do have 
a lower but nevertheless significant association with rejection. In 
the absence of convincing clinical data for NCB HLA antibodies 
in other solid organ transplants, they should also be treated with 
caution.
The relationship of positive bead assay antibody results with 
other assays is an important aspect of interpretation. There is 
universal agreement that an HLA antibody detectable by the 
bead assay which results in a positive CDC crossmatch is a 
contraindication to renal transplantation. However, a negative 
CDC crossmatch in such a situation is less clear cut. The MFI 
cut off for such a scenario is of the order of 10,000 below which 
the CDC crossmatch may be negative, but this may vary from 
laboratory to laboratory based on the sensitivity of the CDC 
crossmatch and the performance of the SAB under local condi-
tions. Some centers have reported an increased risk of rejection 
in such patients, others have observed no effect. However, group 
analyses of such patient groups can mask individual patients 
whose negative outcome has been influenced by bead + CDC 
negative antibodies. Some centers recommend the use of a flow 
crossmatch in such patients. A negative flow and CDC cross-
match may be an indicator that transplantation can proceed. 
In most cases, this occurs in the presence of a low MFI by the 
SAB assay. However, the point must again be stressed that the 
interpretation of multiple assay results must occur in the context 
of the patient’s history.
In some centers the CDC crossmatch has been replaced with 
the VXM. The inherent risk in this approach is that some patients 
will be denied a transplant in what would be a negative CDC 
situation and with HLA antibodies which may ultimately prove 
to be not graft damaging. The confounding factors such as pro-
zone and denatured HLA on beads need careful consideration 
and analysis when relying on virtual crossmatching as the final 
pretransplant determinant of compatibility.
Published results using the LUXM crossmatch technique to 
date suggest that there are too many unresolved issues to recom-
mend this technique as a stand-alone method for solid organ 
transplant allocation.
FUTURe DiReCTiONS
The introduction of solid phase assays ushered in a new era in 
antibody detection both in pre- and posttransplant patients. 
However, the question of B cell presensitization in patients whose 
primary antigenic stimulus was years previously and no longer 
have detectable circulating antibodies still represents a challenge. 
This problem was referred to briefly in the section on MFI where 
levels of antibody below the accepted level for positivity in previ-
ously grafted patients or multiparous females should be flagged as 
a potential problem as it may indicate a state of presensitization. 
Knowing the HLA genotype of previous transplant donors or 
the biological father of the multiparous patients’ children can be 
useful in this regard.
Cardiac grafts in multiparous females with a negative CDC 
crossmatch have a higher incidence of rejection if the donor 
shares an HLA with the father of the patient’s children (82) even 
when the primary immunizing pregnancy was up to 30  years 
previously, demonstrating the long-term effect of memory T and 
B cells. A comparable study considering HLA epitopes rather 
than broad antigens has not been reported.
More recently, Mulder et  al. (83) used HLA tetramers 
to study the peptide dependency of HLA antibodies. This 
technology was utilized by Zachary et  al. (84) to investigate 
the incidence of HLA class I memory B cells in patients with 
a history of HLA antibodies, but shown to be HLA antibody 
negative when testing current sera samples. Using tetramers 
labeled with PE and a labeled CD19 antibody to identify B cells, 
flow cytometry identified a percentage of cells which bound 
to the HLA tetramers. The incidence of bound tetramers was 
significantly greater in previously HLA immunized compared 
with non-immunized individuals indicating the presence of 
memory B cells.
A recent report using the ELISPOT assay and HLA class II 
biotinylated molecules has described the detection of HLA class 
II-specific memory cells (85) indicating this assay is a useful 
tool for identifying presensitization in the absence of circulating 
antibodies (86).
In addition to previously grafted patients and multiparous 
patients, the use of this technology has potential in monitoring 
patients who have undergone desensitization protocols prior 
to transplantation. Depending on the type of desensitization 
procedure used, it is useful to establish if memory B cells can be 
detected in patients whose circulating HLA antibody is no longer 
detected after treatment.
CONCLUSiON
The introduction of solid phase and in particular bead-based 
assays, for detection of HLA antibodies has revolutionized 
clinical management of organ transplant patients. For the first 
time, laboratory scientists and clinicians are in a position to fully 
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reveal a patients immunological status. This technological break-
through coupled with HLA sequencing data, which permits the 
identification of epitopes to which HLA antibodies are directed 
provides a unique opportunity to maximize the transplant suc-
cess rate. This new found enthusiasm however is tempered by 
the fact that there are still areas of both technical and clinical 
contention which require resolution, such as the role of NCB 
HLA antibodies and the detection of antibodies to denatured 
HLA antibodies and their role if any in graft rejection. With 
this rapid rate of evolution of HLA antibody testing technology, 
it is imperative that laboratory-based scientists and clinicians 
communicate on an individual patient basis. Having regard to 
the immunological history of the patient when interpreting HLA 
antibody results is critical in maximizing the positive clinical 
impact of this technology.
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